Chemistry: analytical and immunological testing – Biospecific ligand binding assay
Reexamination Certificate
2006-07-11
2006-07-11
Winkler, Ulrike (Department: 1648)
Chemistry: analytical and immunological testing
Biospecific ligand binding assay
C424S009100, C424S009200, C424S134100, C424S136100, C424S185100, C435S004000, C435S007100, C530S300000, C530S323000, C530S332000, C530S344000
Reexamination Certificate
active
07074620
ABSTRACT:
Method for reducing the level and/or activity of a target protein in a eukaryotic cell via activation of ubiquitination of the target protein wherein the cell is contacted with the compound having a ubiquitination recognition element covalently linked to a target protein binding element. The ubiquitination and recognition element can bind to either the E3 or E2 elements of the ubiquitination system and the target protein binding element is able to bind specifically to the target protein. The target protein binding element has a molecular weight of less than 30,000 and has a binding affinity for the target protein greater than 105M31 1.
REFERENCES:
patent: 5122463 (1992-06-01), Varshavsky et al.
patent: 5766927 (1998-06-01), Baker et al.
patent: 6306663 (2001-10-01), Kenten et al.
patent: 2002/0068063 (2002-06-01), Deshaies et al.
patent: 0 626 450 (1994-11-01), None
patent: WO 98/23283 (1998-06-01), None
patent: WO 99/18989 (1999-04-01), None
patent: WO 00/22110 (2000-04-01), None
patent: WO 00/75184 (2000-12-01), None
Krishnamoorthy et al. Chapter 3: Peptide metabolism by gastric, pancreatic and lysosomal proteinase, In: Peptide Based Drug Design, ed. Taylor et al. (1995) American Chemical Society, pp. 47-68.
Chomienne et al., Discrepancy between in vitro and in vivo passaged U-937 human leukemic Cells: Tumerorigenicity and sensitivity to differentiating drugs. In Vivo (1988).
Harlow et al. In Antibodies: A laboratory manual, ed. Harlow et al. (1988) pp. 27-28.
Matthews J., Fundamentals of receptor, enzyme and transport kinetics, CRC Press, Inc. (1993) pp. 28-30, 121-126).
Vallabhajosula et al. Non-specific binding of transferring and lactoferrin to polystyrene culture tubes: role of the radioligand. European Journal of Nuclear Medicine (1983) vol. 8, No. 5, abstract only.
Sakamota et al. Protacs: Chimeric molecules that target proteins to the Skp1-cullin-Fbox complex for ubiquitination and degradation. Proceedings of the National Academy of Science (2001) pp. 8554-8559.
Briesewitz, Robert, et al, “Affinity modulation of small-molecule ligands by borrowing endogenous protein surfaces,”Proc. Natl. Acad. Sci. USA, vol. 96, pp. 1953-1958, Mar. 1999.
Kwon, Yong Tae, et al, “Bivalent Inhibitor of the N-end Rule Pathway,”The Journal of Biological Chemistry, vol. 274, No. 25, pp. 18135-18139, Jun. 18, 1999.
Solomon, Vered, et al, “The N-end Rule Pathway Catalyzes a major Fraction of the Protein Degradation in Skeletal Muscle,”The Journal of Biological Chemistry, vol. 273, No. 39, pp. 25216-25222, Sep. 25, 1998.
Yewdell, J., et al, “Generating MHC class I ligands from viral gene products,”Immunological Review, vol. 172, Dec. 1999 (Abstract only).
Souroujon, M.C., et al, “Peptide modulators of protein-protein interactions in intracellular signaling,”Nature Biotechnology, vol. 16, No. 10, 1998 (Abstract only).
Liu, Jun O., “Recruitment of proteins to modulate protein-protein interactions,”Chemical Biology, vol. 6, No. 8, pp. 213-215, Aug. 1999.
Fassina, G., “Complementary peptides as antibody mimetics for protein purification and assay,”Immunomethods, vol. 5, No. 2, 1994 (Abstract only).
Varshavsky A., The N-end rule: functions, mysteries and uses. Proceeding of the National Academy of Sciences, vol. 93, pp. 12142-12149 (1996).
Scheffner, M., et al; “Targeted degradation of the retinoblastoma protein by human papillomavirus E7-E6 fusion proteins”;The EMBO Journal, vol. 11, No. 7.; pp. 2425-2431 (1992) xp001019110.
Johnson, E.S., et al; “Cis-trans recognition and subunit-specific degradation of short-lived proteins”;Letters to Nature; vol. 346, pp. 287-291 (1990) XP002125275.
Patton, E.E., et al; “Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F-box hypothesis”;Trends in Genetics; vol. 14, No. 6; pp. 236-243 (1998) XP004121083.
Belshaw, P.J., et al; “Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins”;Proc. Natl. Acad. Sci.; vol. 93; pp. 4604-4607 (1996) XP002919616.
King, P.J., et al; “Structure-Activity Relationships: Analogues of the Dicaffeoylquinic and Dicaffeoyltartaric Acids as Potent Inhibitors of Human Immunodeficiency Virus Type I Integrase and Republication”;J. Med. Chem.; vol. 42; pp 497-509 (1999) XP000919203.
Supplementary Partial European Search Report, Jul. 11, 2005.
Kenten John H.
Roberts Steven F.
Nixon & Vanderhye
Proteinix, Inc.
Winkler Ulrike
LandOfFree
Controlling protein levels in eucaryotic organisms does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlling protein levels in eucaryotic organisms, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlling protein levels in eucaryotic organisms will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3583714